Guide
Everything providers need to know about the two types of compounding pharmacies — regulations, prescriptions, quality standards, and how each model affects your practice.
Get Provider Access
Talk with our clinical team about GLP-1, hormones, aesthetics, and specialty compounding. We'll verify your credentials and get you up and running.
Schedule a Call →By scheduling, you agree to our Privacy Policy.
Compounding pharmacies in the United States operate under two distinct regulatory frameworks: Section 503A and Section 503B of the Federal Food, Drug, and Cosmetic Act. Understanding the difference is essential for providers choosing a compounding partner.
A 503A pharmacy compounds medications for individual patients based on valid prescriptions from licensed providers. These pharmacies are primarily regulated at the state level and must comply with state pharmacy boards and USP compounding standards (795, 797, 800).
Key characteristics of a 503A pharmacy:
A 503B outsourcing facility is FDA-registered and can compound medications without individual patient prescriptions. 503B facilities operate under federal cGMP standards and are governed by a different regulatory framework than 503A pharmacies.
Key characteristics of a 503B facility:
| Feature | 503A Pharmacy | 503B Outsourcing Facility |
|---|---|---|
| Regulation | State pharmacy boards | FDA (federal) |
| Prescriptions | Patient-specific Rx required | Operates under federal 503B framework |
| Batch Size | Individual patient quantities | Larger anticipatory batches under FDA framework |
| Distribution | Primarily in-state (exceptions exist) | Multi-state distribution permitted |
| Quality Standards | USP 795/797/800 | cGMP (more stringent facility standards) |
| FDA Inspections | Not routinely — state boards inspect | Yes — regular FDA inspections |
| Adverse Event Reporting | State-level requirements | Mandatory FDA reporting |
| Bulk Anticipatory Compounding | Not permitted under 503A | Permitted under federal 503B framework |
The right choice depends on your practice model and compound needs:
Choose a 503A pharmacy when:
Choose a 503B facility when:
The 503A vs 503B distinction is particularly relevant for GLP-1 compounds like semaglutide and tirzepatide. Under 503A, each GLP-1 compound is prepared for a specific patient based on a provider's prescription — particularly relevant during FDA-designated shortages when compounding of these molecules is legally permitted.
Promise Pharmacy operates as a licensed 503A compounding pharmacy. We compound individual patient prescriptions under state regulation with USP 795/797/800 compliance. Every compound is quality-tested and prepared specifically for your patient.
This model gives providers the flexibility of custom formulations — any strength, any dosage form, any combination — with the quality assurance of third-party potency and sterility testing on every batch.
FAQ